Ocular Melanoma Clinical Trial
Official title:
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma
The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity. However, ablation of the eyeball is sometimes necessary after proton therapy in the case of neovascular glaucoma. This complication occurs in 7 to 47% of cases (depending on the size of the tumor) and is associated with hypersecretion of Vascular Endothelial Growth Factor (VEGF) related to necrotic and inflammatory tumor tissue after proton therapy or ischemic retina. The intravitreal injections of anti-VEGF are used in the treatment of neovascular radicular glaucoma without avoiding enucleation in all cases. The investigators propose to study the prevention of neovascular glaucoma by intravitreal prophylactic administration of anti-VEGF.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
| Completed |
NCT01200238 -
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Completed |
NCT01355120 -
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
|
Phase 2 | |
| Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT05187884 -
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
|
Phase 2 | |
| Recruiting |
NCT02909517 -
The Role of Inflammation in Ocular Tumours
|
||
| Withdrawn |
NCT00621439 -
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
|
N/A | |
| Terminated |
NCT00346372 -
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
|
||
| Not yet recruiting |
NCT06432660 -
Eye Plaque Brachytherapy for Ocular Melanoma
|
||
| Completed |
NCT01893099 -
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
|
Phase 1 | |
| Completed |
NCT00351728 -
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
|
N/A | |
| Active, not recruiting |
NCT03528408 -
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT03052127 -
Study in Subjects With Small Primary Choroidal Melanoma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01930968 -
Definity for Ultrasound of Intraocular Tumors
|
||
| Recruiting |
NCT00168870 -
Study of Metastatic Ocular Melanoma
|
Phase 2 | |
| Completed |
NCT02519322 -
Neoadjuvant and Adjuvant Checkpoint Blockade
|
Phase 2 | |
| Recruiting |
NCT06007690 -
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
|
Phase 3 | |
| Active, not recruiting |
NCT04417530 -
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
|
Phase 2 |